The TLR4-Active Morphine Metabolite Morphine-3-Glucuronide Does Not Elicit Macrophage Classical Activation In Vitro by Samira Khabbazi et al.
fphar-07-00441 November 15, 2016 Time: 15:51 # 1
ORIGINAL RESEARCH
published: 17 November 2016
doi: 10.3389/fphar.2016.00441
Edited by:
Amit K. Tiwari,
University of Toledo, USA
Reviewed by:
Alvaro Diaz,
University of the Republic, Uruguay
Wang Lingzhi,
National University of Singapore,
Singapore
Hemlata Sukhija,
Children’s Hospital Los Angeles, USA
*Correspondence:
Marie-Odile Parat
m.parat@uq.edu.au
Specialty section:
This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Pharmacology
Received: 05 September 2016
Accepted: 04 November 2016
Published: 17 November 2016
Citation:
Khabbazi S, Xie N, Pu W, Goumon Y
and Parat M-O (2016)
The TLR4-Active Morphine Metabolite
Morphine-3-Glucuronide Does Not
Elicit Macrophage Classical Activation
In Vitro. Front. Pharmacol. 7:441.
doi: 10.3389/fphar.2016.00441
The TLR4-Active Morphine
Metabolite Morphine-3-Glucuronide
Does Not Elicit Macrophage
Classical Activation In Vitro
Samira Khabbazi1, Nan Xie1, Wenjun Pu1, Yannick Goumon2 and Marie-Odile Parat1*
1 Pharmacy Australia Centre of Excellence, School of Pharmacy, University of Queensland, Woolloongabba, QLD, Australia,
2 CNRS UPR3212, Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche
Scientifique–University of Strasbourg, Strasbourg, France
Macrophages are abundant in the tumor microenvironment where they adopt a
pro-tumor phenotype following alternative polarization induced by paracrine factors
from cancer and stromal cells. In contrast, classically activated macrophages have
tumoricidal activities, such that the polarization of tumor-associated macrophages
has become a novel therapeutic target. Toll-like receptor 4 engagement promotes
classical activation of macrophages, and recent literature suggests TLR4 agonism to
prevent metastasis and promote survival in experimental metastasis models. A growing
number of studies indicate that TLR4 can respond to opioids, including the opioid
receptor-inactive morphine metabolite morphine-3-glucuronide (M3G). We measured
the activation of TLR4 in a reporter cell line exogenously expressing TLR4 and TLR4
co-receptors, and confirmed that M3G weakly but significantly activates TLR4. We
hypothesized that M3G would promote the expression of classical activation signature
genes in macrophages in vitro. We exposed mouse and human macrophage cell
lines to M3G or the TLR4 activator lipopolysaccharide (LPS), alone or in combination
with interferon gamma (IFN-γ). The classical macrophage activation markers tested
were iNOS, CD86, IL-6, or TNF-α in RAW 264.7 cells and IL-6, IL-12, IL-23, TNF-α,
CXCL10, and CXCL11 in THP1 cells. Our results show that despite exhibiting TLR4-
activation ability, M3G does not elicit the expression of classical activation markers in
LPS-responsive macrophages.
Keywords: classically activated macrophages, tumor-associated macrophages, morphine-3-glucuronide, toll like
receptor 4, lipopolysaccharide, interferon gamma, THP1, RAW267.4
INTRODUCTION
The possibility that the pain management of cancer surgery patients can be exploited to
significantly reduce the risk of local or metastatic recurrence is generating tremendous interest.
Opioids still play a major role in perioperative patient care, however, they are reported to modulate
tumor growth and metastasis, with discrepant evidence from both in vitro and in vivo experimental
Abbreviations: DAMP, danger associated molecular pattern; HMG1, high mobility group box 1; SEAP, secreted embryonic
alkaline phosphatase.
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settings (Afsharimani et al., 2011, 2015). Morphine has been
tested for its effect on cancer cells, immune cells and endothelial
cells grown individually (reviewed in Afsharimani et al., 2011; Xie
and Parat, 2015). Furthermore, we have unveiled the ability of
morphine to modulate the interaction between cancer and non-
cancer cells important in the tumor microenvironment, including
endothelial cells and macrophages (Afsharimani et al., 2014;
Khabbazi et al., 2015, 2016).
Tumor-associated macrophages (TAMs) are critical
determinants of cancer cell invasiveness, their metastatic
potential as well as angiogenesis (Noy and Pollard, 2014; Bronte
and Murray, 2015). Macrophages display great functional
plasticity in response to specific pathological contexts (Murray
et al., 2014) and play a key role in the biology of solid tumors
where they constitute up to 50% of the cell population (Solinas
et al., 2009). Alternatively activated (M2) macrophages promote
tumor aggressiveness. In contrast, classically activated (M1)
macrophages are considered to have anti-tumor properties (Noy
and Pollard, 2014). Reprogramming TAMs from an M2-like
phenotype to an M1-like, pro-inflammatory phenotype has the
potential to induce anti-tumor activity by rendering the tumor
immunogenic (Georgoudaki et al., 2016).
TLR4 plays a key role in macrophage M1 polarization.
TLR4 responds to gram negative bacteria membrane component
lipopolysaccharide (LPS), which binds to co-receptor MD2.
After activation at the cell surface by LPS, TRL4 activates two
signaling pathways. The first one, via the adaptor proteins
Toll-IL-1 receptor domain-containing adaptor protein (TIRAP)
and myeloid differentiation factor 88 (MyD88) results in the
induction of pro-inflammatory cytokines. The second one
via TRIF-related adaptor molecule (TRAM) and Toll/IL-1
receptor containing adaptor inducing IFN-β (TRIF) mediates the
induction of type I interferons (O’Neill et al., 2013). LPS elicits
classical activation gene expression alone or synergistically with
IFN-γ. TLR4 activation by other ligands, such as the DAMP
HMG1 protein also reprograms macrophages toward a M1
phenotype (Su et al., 2016).
We have previously demonstrated the ability of morphine
to prevent macrophage M2 polarization elicited by tumor cells
(Khabbazi et al., 2015). In the current study, we hypothesized that
the opioid receptor-inactive morphine metabolite morphine-3-
glucuronide (M3G), which is documented to be active at TLR4
(Hutchinson et al., 2010; Stevens et al., 2013), would modulate
the M1 polarization of macrophages in vitro.
MATERIALS AND METHODS
Materials
Cell culture medium, serum and supplements, primers and real-
time PCR reagents were from Life Technologies (Mulgrave,
VIC, Australia). M3G was from Novachem (Collingwood,
VIC, Australia). QUANTI-BlueTM, NormocinTM, and HEK-
BlueTM Selection reagent were from Jomar Life Research
(Scoresby, VIC, Australia). Other reagents were purchased from
Sigma-Aldrich (Castle Hill, NSW, Australia) unless otherwise
specified.
Cell Culture
The TLR4 reporter cell line HEK-BlueTM-hTLR4 (Jomar Life
Research, Scoresby, VIC, Australia) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% (v/v)
FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 100 µg/ml
NormocinTM and 1X HEK-BlueTM Selection reagent. These
human embryonic kidney 293 cells are engineered to express
hTLR4 and MD-2/CD14 co-receptor genes, together with a SEAP
reporter gene under NF-κB and AP-1 control. THP1 human
monocytes were grown in Roswell Park Memorial Institute
medium (RPMI-1640) medium supplemented with 10% FBS
(v/v), penicillin (100 units/ml) and streptomycin (100 µg/ml). In
some experiments, THP1 differentiation was induced by PMA
as follows: THP1 cells were treated with 50 nM PMA in RPMI-
1640 containing 10% (v/v) FBS, 50 units/ml penicillin, 50 µg/ml
streptomycin for 48 h. The medium was replaced with serum-
free RPMI medium, and cells were incubated with different
concentrations of M3G (1, 5, 10, or 20 µM) or LPS (0.001–
10 ng/ml) alone or in combination with 10 ng/ml IFN-γ for
another 12 h. Mouse RAW264.7 macrophages were seeded in
DMEM containing 5% FBS (v/v), penicillin (100 units/ml) and
streptomycin (100 µg/ml) and incubated overnight. Cells were
further treated with different concentrations of M3G (1, 5, 10, or
20 µM) or 0.01 ng/ml LPS alone or in combination with 1 ng/ml
IFN-γ in serum-free DMEM medium for 12 h. All cell lines were
kept in an incubator with a humidified atmosphere (37◦C) and
5% carbon dioxide (CO2).
HEK-BlueTM-hTLR4 Assay (TLR4
Signaling Assay)
The determination of TLR4 activation in HEK-BlueTM-hTLR4
cells relies on NF-κB-dependent production of SEAP detected
using a colorimetric substrate placed in the cell culture medium.
The cells were seeded (10,000 cells/well) in a 96-well plate and
incubated for 48 h. The medium was replaced with serum-free
medium containing the drugs to be tested, and cells incubated
for 12 h. The supernatant of treated cells (20 µl/well) was added
to QUANTI-BlueTM substrate pre-warmed at 37◦C (180 µl/well)
and incubated for 4 h at 37◦C. The plates were read at a
wavelength of 655 nm with a spectrophotometer (Bio-Rad
Laboratories Inc.). Results are expressed as the percentage of
absorbance at 655 nm observed for control cells.
Quantitative RT-PCR
In order to detect and quantify the expression of transcripts
of specific genes, real-time reverse transcriptase polymerase
chain reaction (Real time RT-PCR) was performed. Total
RNA was isolated from RAW264.7 or THP1 cells and purified
using a Pure linkTM RNA Mini Kit (Life Technologies,
Melbourne, VIC, Australia). Purified RNA concentration then
was determined via 260 nm absorbance (A260) using a nano-
drop spectrophotometer (Thermo Fisher Scientific, Scoresby,
VIC, Australia). Isolated RNA (2000 ng) was reverse transcribed
to complementary DNA using High-Capacity cDNA reverse
transcription kit (Life Technologies, Melbourne, VIC, Australia).
Amplification and quantification of cDNA was assessed, using
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TaqManTM Fast Universal PCR Master Mix (Life Technologies,
VIC, Australia) with AmpliTaq GoldTM DNA Polymerase
and TaqManTM Gene Expression Assays including human
primers : IL-6 (Hs00985639-m1), IL-12 (Hs01011518-m1),
IL-23 (Hs00900828-g1), TNFα (Hs01113624-g1), CXCL10
(Hs01124252-g1), and CXCL11(Hs04187682-g1) or mouse
primers: iNOS (Mm00440502-m1), IL-6 (Mm00446190-m1),
TNFα (Mm00443258-m1), CD86 (Mm00444543-m1) in a
StepOnePlus 7500 real time PCR system (Applied Biosystems,
Carlsbad, CA, USA). Quantification was performed using the
comparative critical threshold (Ct) method in which the amount
of target gene is normalized to 18S ribosomal RNA (18S rRNA)
control gene (Schmittgen and Livak, 2008).
Statistical Analysis
Data are shown as mean ± SEM of data obtained in at
least 3 independent experiments unless otherwise indicated in
the figure legend. Statistical analysis was performed on all
data using Graphpad Prism software (version 6.04). Differences
between group means were compared using one-way ANOVA
or one-tailed Student’s t-test where appropriate. Differences were
considered statistically significant when p< 0.05.
RESULTS
M3G Activates TLR4, but Inhibits
LPS-Induced TLR4 Activation in a
Reporter Cell Line
We made use of the HEK-BlueTM cells to measure TLR4
activation (Supplementary Figure 1). A dose–response curve of
LPS was first generated (Supplementary Figure 1A) and showed
a maximal activation of ∼500% compared to untreated cells.
We tested the ability of M3G to activate TLR4 in this system
(Supplementary Figure 1B) and showed at 1 µM and above
a modest but statistically significant activation plateauing at
∼150–160% of control with maximal activation at and above
10 µM. We verified that apparent TLR4 activation was not due
to LPS contamination of the M3G solution. To that extent,
we repeated the activation by M3G in the presence of the
LPS-binding antibiotic polymyxin B. Polymyxin B blunted the
activation induced by LPS (Supplementary Figure 1C) but had
no effect on that induced by M3G (Supplementary Figure 1D),
confirming M3G was free from LPS. Opioid receptor agonists
and antagonists have been shown to act as inhibitors of TLR4
activation by its ligand LPS (Stevens et al., 2013). We tested
the ability of M3G to modulate LPS-induced TLR4 activation
in this system (Supplementary Figure 1E). The results show
significant inhibition of the activation induced by 1 ng/ml LPS
by concentrations of M3G as low as 0.1 µM.
M3G Does Not Elicit M1 Differentiation of
RAW264.7 Macrophages
To examine the effect of M3G on RAW264.7 macrophages,
we first tested mRNA expression of a series of recognized
M1 markers in response to LPS, interferon gamma (IFN-γ),
or LPS and IFN-γ in combination (Supplementary Figure 2).
Our aim was to use a concentration of LPS that would induce
M1 differentiation, elicit a level of TLR4 activation in the
range of that induced by M3G, and allow an increased effect
of the combination IFN-γ + LPS compared to LPS or IFN-
γ alone. The expression of inducible nitric oxide synthase
(iNOS), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-
α) was induced by 0.01 ng/ml LPS and the induction was
enhanced by the co-administration of IFN-γ to the cells. The
expression of CD86 was not increased by 0.01 ng/ml LPS but
the combination LPS + IFN-γ resulted in increased expression
compared to either cytokine alone. We then used these markers
to evaluate the effect of M3G on M1 macrophage polarization
(Figure 1). The results show that M3G up to a concentration
of 20 µM did not affect the expression of iNOS, CD86, IL-6,
or TNF-α by RAW 264.7 cells. In contrast, except for CD86,
the expression of these markers was induced by 0.01 but not
0.001 ng/ml LPS. We then tested whether M3G increased the
expression of M1 markers when applied in combination with
IFN-γ (Figure 2). There was a trend toward increased M1
marker expression with increasing concentrations of M3G in
the presence of IFN-γ but except in the case of TNF-α, no
statistical significance was detected (One-way ANOVA analysis
with Dunnett’s multiple comparisons M3G + IFN-γ vs IFN-
γ alone). The results indicate the TLR4 activation by M3G
is below the threshold required to elicit M1 differentiation in
RAW264.7 cells, whether applied alone or in combination with
IFN-γ.
Effect of M3G on LPS-Induced TLR4
Activation in RAW264.7 Cells
Morphine-3-glucuronide acted as a weak activator of TLR4 in the
reporter cell line, but also as an inhibitor of LPS-induced TLR4
activation (Supplementary Figure 1D). We thus tested whether
M3G could alter the LPS-induced TLR4 activation in RAW264.7
cells. Cells were incubated in the presence of LPS (1 ng/ml)
and M3G up to a concentration of 20 µM. The expression of
iNOS, CD86, IL-6, and TNF-α was assessed (Figure 3). The
results showed a trend toward decreased LPS induction of the
tested genes by M3G. There was no statistical significance in
this reduction except for iNOS with 1 µM M3G and IL-6
with 10 µM M3G (one-way ANOVA with Dunnet’s multiple
comparisons, LPS + M3G vs. LPS alone). To rule out that the
effect of M3G could be at TLR4 expression rather than activation
level, we verified that M3G had no effect on TLR4 expression
(Supplementary Figure 3).
Effect of M3G on PMA-Differentiated
THP1 Cells
We next tested the human cell line THP1. We first examined
whether PMA differentiation of the THP1 monocytic cell line
to macrophages modulated TLR4 expression and subsequently
the cell response to LPS. THP1 cells were incubated in the
presence or absence of 50 nM PMA for 48 h and the mRNA
expression of TLR4 and a series of M1 markers was assessed
using RT-PCR (Supplementary Figure 4). The results showed
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FIGURE 1 | Effect of M3G on expression of M1 markers in RAW264.7 cells. RAW264.7 cells (2 × 105 cells/well) were exposed to 0.001 or 0.01 ng/ml LPS, or
M3G at the indicated concentrations (1, 5, 10, and 20 µM). The mRNA levels of iNOS, CD86, IL-6, or TNF-α were determined by qRT-PCR. Results are shown
relative to control (untreated) RAW264.7 cells. Results are shown as mean ± SEM, n = 4–7 independent experiments. ∗∗p < 0.01, LPS vs. control cells.
FIGURE 2 | Effect of M3G co-administered with IFN-γ on expression of M1 markers in RAW264.7 cells. RAW264.7 cells (2 × 105 cells/well) were treated
with 1 ng/ml IFN-γ alone or together with M3G (1, 5, 10, or 20 µM) for 12 h. Expression of iNOS, TNF-α, IL-6, and CD86 mRNA was determined by qRT-PCR.
Results are shown relative to control (untreated) RAW264.7 cells. Mean ± SEM is shown, n = 4 independent experiments. ∗p < 0.05, M3G + IFN-γ vs. IFN-γ alone,
one-way ANOVA analysis with Dunnett’s multiple comparisons. Results are shown as mean ± SEM, n = 4–7 independent experiments.
FIGURE 3 | Effect of M3G on LPS-induced TLR4 activation in RAW264.7 cells. Cells were exposed to 1 ng/ml LPS alone or in combination with different
concentrations of M3G (1, 5, 10, and 20 µM) for 12 h. The mRNA expression of M1 polarization markers was assessed by real-time RT-PCR. Results are expressed
relative to LPS-treated cells. Results are shown as mean ± SEM, n = 3 independent experiments. ∗p < 0.05, M3G vs. control cells, One-way ANOVA analysis with
Dunnett’s multiple comparisons.
a significant increase in TLR4 expression level (∼fourfold) in
PMA-treated THP1 cells compared to the control cells. Moreover,
the induction of some (IL-23, IL-12, IL-6, TNF-α), but not all
M1 markers tested in response to LPS was increased in PMA-
differentiated THP1 cells compared to undifferentiated THP1
cells. Of note, iNOS was not induced by LPS regardless of
PMA treatment, and CD86 was weakly induced. Surprisingly,
CXCL10 and CXCL11 expression was induced more efficiently
in undifferentiated THP1 than in PMA-differentiated THP1.
We next tested the effect of LPS (0.01 ng/ml) and IFN-γ
(10 ng/ml) alone or in combination on M1 marker expression
in PMA-differentiated THP1 cells. The expression of IL-6, IL-
12, IL-23, TNF-α, CXCL10, and CXCL11 mRNA was induced
by LPS, by IFN-γ and the induction was enhanced by the co-
administration of IFN-γ and LPS to the cells (Supplementary
Figure 5).
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FIGURE 4 | Effect of M3G on the expression of M1 markers in PMA-differentiated THP1 cells. THP-1 cells were incubated with 50 nM PMA for 48 h. Cells
were then treated with M3G (1, 5, 10, or 20 µM) for 12 h. LPS (0.001 and 0.01 ng/ml) was also used as a comparison. The expression of IL-6, IL-12, IL-23, TNF-α,
CXCL10, and CXCL11 was determined by qRT-PCR. ∗p < 0.05, ∗∗p < 0.01 LPS vs. control cells, One-way ANOVA analysis with Dunnett’s multiple comparisons.
Results are shown as mean ± SEM, n = 4–12 independent experiments.
We then assessed whether M3G can induce the expression
of M1 markers when applied to PMA-differentiated THP1 cells
(Figure 4). M3G (1–20 µM) had no effect the expression of
IL-6, IL-12, IL-23, TNF-α, CXCL10, or CXCL10 by THP1 cells.
LPS, used as a positive control, induced increased expression
of these markers at 0.01 but not 0.001 ng/ml. We then
evaluated whether M3G could induce M1 polarization when co-
administered with IFN-γ (Figure 5). None of the tested markers
had increased expression in cells treated with IFN-γ + M3G up
to 20 µM compared to cells treated with IFN-γ alone. These
results show that M3G, whether alone or in combination with
IFN-γ, does not elicit M1 polarization in PMA-treated THP1
cells.
Effect of M3G on LPS-Induced TLR4
Activation in THP1 Cells
We tested whether M3G could alter the LPS-induced TLR4
activation in PMA-differentiated THP1 cells. PMA-treated THP1
cells were incubated in the presence of LPS (1 ng/ml) and M3G
up to a concentration of 20 µM. The expression of IL-6, IL-12,
IL-23, TNF-α, CXCL10, and CXCL11 was assessed. There was
an apparent ∼70% decrease in the LPS-induced expression of
CXCL10 and CXCL11 by M3G which was statistically significant
(One-way ANOVA with Dunnet’s multiple comparisons, LPS +
M3G vs LPS alone). Interestingly, the effect of M3G did not
seem to be dose-dependent (Figure 6). We verified that M3G
had no effect on TLR4 expression in THP1 cells (Supplementary
Figure 3).
Effect of M3G on Poly ICLC-Induced M1
Polarization Marker Expression
To test whether the inhibitory effect of M3G on LPS-induced
M1 marker expression was specific for the TLR4 pathway,
we evaluated the effect of M3G on M1 marker induction
by another TLR, namely TLR3. To that extent, we exposed
RAW264.7 or THP1 to the TLR3 ligand Poly ICLC and measured
mRNA expression of the markers whose expression was affected
by M3G in LPS experiments, namely iNOS and IL-6 for
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FIGURE 5 | Effect of M3G co-administered with IFN-γ on expression of M1 markers in PMA-differentiated THP1 cells. THP-1 cells were treated with
50 nM PMA for 48 h and exposed to 10 ng/ml IFN-γ alone or in combination with different concentrations of M3G (1, 5, 10, or 20 µM) for another 12 h. The
expression of IL-6, IL-12, IL-23, TNF-α, CXCL10, and CXCL11 mRNA was determined by qRT-PCR. Results are shown relative to control differentiated THP-1 cells.
Results are shown as mean ± SEM, n = 7–11 independent experiments.
RAW264.7 and CXCL10 and CXCL11 for THP1 cells. The results
(Supplementary Figure 6) show no decrease of the poly ICLC-
induced expression of these markers by M3G, indicating that
M3G interferes somewhat selectively with TLR4-mediated, LPS-
induced M1 macrophage polarization.
DISCUSSION
There is increasing evidence that the morphine metabolite M3G
is active at TLR4 (Hutchinson et al., 2010; Lewis et al., 2010;
Due et al., 2012). Long neglected by researchers because it has
essentially no activity on opioid receptors and is not analgesic
(Milne et al., 1996), this glucuronidated metabolite is produced
in abundance in mice, peaking in the serum at ∼60 µM after i.v.
or s.c. injection, and ∼100 µM after i.p. injection of 80 µmol/kg
of morphine (Handal et al., 2002), and humans, ranging from
0.1 to 24 µM (Lee et al., 2015) or from 0.83 to 39 µM (Netriova
et al., 2006) in morphine-treated oncological patients. Activation
of TLR4 by M3G is proposed to cause neuro-inflammation and
hyperalgesia via central glial and endothelial cells (Lewis et al.,
2010; Grace et al., 2014). Considering the crucial role of TLR4
activation on innate immune responses, it becomes important to
test whether M3G could mimic the effects of LPS on macrophage
M1 polarization in vitro.
In our experiments, while eliciting TLR4 activation in
the HEK-BlueTM-hTLR4 cells in a modest (at most 60%
above control cells, compared to 500% of control obtained
with LPS) but significant fashion, M3G strongly inhibited
LPS-induced TLR4 activation in the same cell line (up
to 45% inhibition at 30 and 100 µM). The activation of
TLR4 is in agreement with previous findings making use of
reporter lines overexpressing TLR4 (Hutchinson et al., 2010;
Lewis et al., 2010). M3G activation of TLR4 has also been
documented in vitro using cells that endogenously express
TLR4 (Lewis et al., 2010; Due et al., 2012; Grace et al.,
2014). The inhibition by M3G of LPS-induced activation of
TLR4 is a novel finding, albeit expected since similar results
have been obtained using other opioids, namely morphine,
fentanyl, naltrexone, and β-funaltrexamine (β-FNA) (Stevens
et al., 2013). Immunomodulating drugs targeting TLR4 are
actively investigated in cancer, where TLR4 persistent activation
can induce chronic inflammatory conditions contributing to
carcinogenesis, while TLR4 agonists can induce anti-tumor
immunity (Awasthi, 2014). A TLR4-active agent that promotes
anti-tumor immunity while decreasing inflammatory response
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FIGURE 6 | Effect of M3G on LPS-induced TLR4 activation. THP1 cells were treated with 50 nM PMA for 48 h and exposed to 1 ng/ml LPS alone or in
combination with different concentrations of M3G (1, 5, 10, and 20 µM) for another 12 h. The mRNA expression of M1 polarization markers IL-6, IL-12, IL-23,
TNF-α, CXCL10, and CXCL11 was assessed by real-time RT-PCR. Results are expressed relative to LPS-treated, PMA-differentiated THP1 cells. Results are shown
as mean ± SEM, n = 3 independent experiments. ∗p < 0.05, ∗∗p < 0.01 M3G vs. control cells, One-way ANOVA analysis with Dunnett’s multiple comparisons.
would be valuable in cancer therapy (Awasthi, 2014). It would
be interesting to assess opioids in this context, including M3G,
whose activity at TLR4 is proposed to be mediated by its
glucuronidated moiety on the carbon number 3 (Lewis et al.,
2010).
Our preliminary steps to select markers for the experiments
to be conducted with RAW 264.7 and THP1 cells revealed
remarkable differences in the response of these two cell lines
to LPS. For example iNOS was strongly induced in the mouse
but not the human cell line, an interspecies divergence that has
been previously reported (Schroder et al., 2012; Spiller et al.,
2016). We chose markers whose induction with 0.01 ng/ml
LPS was detectable, and further increased with co-treatment by
IFN-γ (Figures 2 and 6). In THP1, the mRNA expression of
CXCL10 and CXCL11 was induced by LPS to a higher extent
in undifferentiated compared to PMA-differentiated cells, even
though PMA resulted in a ∼ fourfold increase in TLR4 mRNA
expression. We nonetheless included CXCL10 and CXCL11 in
our panel of M1 markers because they were both significantly
induced by LPS in PMA-differentiated cells, and they have
been reported to be the genes with the most similar pattern of
expression among all source of macrophages stimulated in vitro
with LPS and IFN-γ (Spiller et al., 2016), indicating they are a
reliable experimental polarization marker.
Our results indicate that neither RAW 264.7 nor PMA-
differentiated THP1 cells respond to M3G alone by increasing
the expression of genes known as M1 markers. This is despite the
activation seen with M3G in the reporter cell line overexpressing
TLR4 and co-receptors, and despite choosing M1 markers that
are induced by LPS in RAW 264.7 and PMA-differentiated THP1
in the same experimental conditions.
RAW 264.7 cells are hypo-responsive to LPS due to a
point mutation affecting surface expression of the TLR4 in
BALB/c mice and cells of BALB/c origin (Tsukamoto et al.,
2013). Nonetheless, they are widely employed in experiments
testing the effect of TLR4 activation in response to LPS and we
established their responsiveness to 0.01 mg/ml LPS. Similarly
negative results were obtained when RAW 264.7 cells were
exposed to M3G in combination with IFN-γ, except for TNFα
mRNA that was statistically higher at two concentrations of
M3G + IFN-γ compared to IFN-γ alone. Likewise, THP1 cells
which are extensively used to study TLR4 response in vitro,
failed to respond to M3G alone or in combination with
IFN-γ by increased expression of M1 polarization markers.
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These results could reflect a quantitatively and/or qualitatively
different response of the TLR4 to M3G compared to LPS. Of
note, we employed LPS as a control at two concentrations,
one of which activated HEK-BlueTM-hTLR4 cells to a similar
extent as M3G (0.001 ng/ml) while the other one elicited
much stronger activation of the HEK-BlueTM-hTLR4 cells than
M3G (0.01 ng/ml). The fact that LPS was able to induce M1
polarization markers at 0.01 ng/ml but not at 0.001 ng/ml,
suggests that TLR4 activation by M3G is below the threshold
needed for the activation of these macrophage cell lines.
In silico studies using the structure of the TLR4 and MD-2
complex documented that opioids dock in the LPS-binding cleft
of MD-2 (Hutchinson et al., 2010). This was confirmed for
M3G, with the additional information that the glucuronic acid
portion of this metabolite interacts closely with residues in MD-
2 known to be important for the activation of TLR4 by LPS
(Lewis et al., 2010). The HEK-BlueTM-hTLR4 reporter cell line
is co-transfected with MD2 and CD14 (in addition to TLR4)
while the RAW 264.7 and THP1 cells rely on endogenously
produced MD2 and CD14. This may lead to better activation
of the HEK-BlueTM-hTLR4 than RAW 264.7 and THP1 by
ligands. However, M3G has been shown to activate endogenously
expressed TLR4, e.g., in the mouse BV2 glial cell line where
M3G elicited increased IL1 production (Lewis et al., 2010), in
central nervous system endothelial cells where it induced TNF-α,
COX2, and PGE2 production (Grace et al., 2014), or in primary
dorsal root ganglion neurons where increased excitability by
M3G was prevented by an inhibitor of the TLR4-MD2 complex
(Due et al., 2012). The possibility that primary cells such as
bone marrow derived macrophages or thioglycollate medium-
elicited macrophages may show a higher response to M3G than
cell lines could be tested in the future to help clarify this
point.
Expression or upregulation of TLR4 has been identified in
tumor cells, and although it is not always the case (Lamrani et al.,
2016), TLR4 activation is mostly reported to stimulate cancer cell
aggressive behavior (Molteni et al., 2006; Ikebe et al., 2009; Liao
et al., 2012; Chung and Kim, 2016; Sun et al., 2016). It has been
proposed that activation of TLR4 on immune cell is protective,
while activation of cancer cell TLR4 promotes aggressiveness
(Afsharimoghaddam et al., 2016). In this context, it would be
interesting to assess whether M3G increases invasiveness of
cancer cell lines that express TLR4.
Inhibition of TLR4 LPS activation by opioids, both OR
agonists and antagonists, has been documented. It was concluded
that opioids inhibit LPS signaling in a non-competitive fashion
(Stevens et al., 2013). Although M3G was not one of the opioids
assessed in this study, the opioid agents tested exhibited an
inhibition of LPS-induced signaling that was not concentration-
dependent, and attributed to either a low capacity site easily
saturated, or a type of non-competitive antagonism (Stevens
et al., 2013). Our results indicate that the LPS-induced expression
of IL6 and chemokines CXCL10 and CXCL11 is affected by
M3G and interestingly, the inhibition does not seem to depend
on the concentration of M3G. In agreement with our results,
opioid receptor-independent inhibition of LPS-induced CXCL10
expression in the brain of mice by treatment with the opioid
antagonist β-funaltrexamine has been documented (Davis et al.,
2015).
Polarization of TAMs to the M1 phenotype can be promoted
by the activation of TLR3 (Liu et al., 2016). There is currently
no information on the effect of M3G on other members of the
TLR family than TLR4. This gap in the literature suggests future
experiments testing if M3G can activate TLR3. Our current data
suggest that M3G does not prevent TLR3-mediated induction of
the expression of M1 polarization markers.
Previous results from our laboratory have shown that
morphine prevents macrophage M2 polarization in in vitro
models mimicking the tumor micro-environment (Khabbazi
et al., 2015). We speculated that M3G, a metabolite produced
in elevated concentrations following morphine administration,
would further tip the balance of tumor macrophage polarization
toward the M1 end of the phenotype spectrum via its reported
ability to activate the TLR4. The results of our study do not point
in this direction, and the effects of M3G on innate immunity will
need further evaluation, including in vivo experiments.
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